Cargando…

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

BACKGROUND: Amplification of aurora kinase A (AK-A) overrides the mitotic spindle assembly checkpoint, inducing resistance to taxanes. RNA interference targeting AK-A in human pancreatic cancer cell lines enhanced taxane chemosensitivity. In this study, a novel AK-A inhibitor, CYC3, was investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Y, Richards, F M, Krippendorff, B-F, Bramhall, J L, Harrington, J A, Bapiro, T E, Robertson, A, Zheleva, D, Jodrell, D I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493865/
https://www.ncbi.nlm.nih.gov/pubmed/23037716
http://dx.doi.org/10.1038/bjc.2012.450
_version_ 1782249340193996800
author Lin, Y
Richards, F M
Krippendorff, B-F
Bramhall, J L
Harrington, J A
Bapiro, T E
Robertson, A
Zheleva, D
Jodrell, D I
author_facet Lin, Y
Richards, F M
Krippendorff, B-F
Bramhall, J L
Harrington, J A
Bapiro, T E
Robertson, A
Zheleva, D
Jodrell, D I
author_sort Lin, Y
collection PubMed
description BACKGROUND: Amplification of aurora kinase A (AK-A) overrides the mitotic spindle assembly checkpoint, inducing resistance to taxanes. RNA interference targeting AK-A in human pancreatic cancer cell lines enhanced taxane chemosensitivity. In this study, a novel AK-A inhibitor, CYC3, was investigated in pancreatic cancer cell lines, in combination with paclitaxel. METHODS: Western blot, flow cytometry and immunostaining were used to investigate the specificity of CYC3. Sulforhodamine B staining, time-lapse microscopy and colony-formation assays were employed to evaluate the cytotoxic effect of CYC3 and paclitaxel. Human colony-forming unit of granulocyte and macrophage (CFU-GM) cells were used to compare the effect in tumour and normal tissue. RESULTS: CYC3 was shown to be a specific AK-A inhibitor. Three nanomolar paclitaxel (growth inhibition 50% (GI(50)) 3 nℳ in PANC-1, 5.1 nℳ in MIA PaCa-2) in combination with 1 μℳ CYC3 (GI(50) 1.1 μℳ in MIA PaCa2 and 2 μℳ in PANC-1) was synergistic in inhibiting pancreatic cell growth and causing mitotic arrest, achieving similar effects to 10-fold higher concentrations of paclitaxel (30 nℳ). In CFU-GM cells, the effect of the combination was simply additive, displaying significantly less myelotoxicity compared with high concentrations of paclitaxel (30 nℳ; 60–70% vs 100% inhibition). CONCLUSION: The combination of lower doses of paclitaxel and CYC3 merits further investigation with the potential for an improved therapeutic index in vivo.
format Online
Article
Text
id pubmed-3493865
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34938652012-11-09 Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells Lin, Y Richards, F M Krippendorff, B-F Bramhall, J L Harrington, J A Bapiro, T E Robertson, A Zheleva, D Jodrell, D I Br J Cancer Translational Therapeutics BACKGROUND: Amplification of aurora kinase A (AK-A) overrides the mitotic spindle assembly checkpoint, inducing resistance to taxanes. RNA interference targeting AK-A in human pancreatic cancer cell lines enhanced taxane chemosensitivity. In this study, a novel AK-A inhibitor, CYC3, was investigated in pancreatic cancer cell lines, in combination with paclitaxel. METHODS: Western blot, flow cytometry and immunostaining were used to investigate the specificity of CYC3. Sulforhodamine B staining, time-lapse microscopy and colony-formation assays were employed to evaluate the cytotoxic effect of CYC3 and paclitaxel. Human colony-forming unit of granulocyte and macrophage (CFU-GM) cells were used to compare the effect in tumour and normal tissue. RESULTS: CYC3 was shown to be a specific AK-A inhibitor. Three nanomolar paclitaxel (growth inhibition 50% (GI(50)) 3 nℳ in PANC-1, 5.1 nℳ in MIA PaCa-2) in combination with 1 μℳ CYC3 (GI(50) 1.1 μℳ in MIA PaCa2 and 2 μℳ in PANC-1) was synergistic in inhibiting pancreatic cell growth and causing mitotic arrest, achieving similar effects to 10-fold higher concentrations of paclitaxel (30 nℳ). In CFU-GM cells, the effect of the combination was simply additive, displaying significantly less myelotoxicity compared with high concentrations of paclitaxel (30 nℳ; 60–70% vs 100% inhibition). CONCLUSION: The combination of lower doses of paclitaxel and CYC3 merits further investigation with the potential for an improved therapeutic index in vivo. Nature Publishing Group 2012-11-06 2012-10-04 /pmc/articles/PMC3493865/ /pubmed/23037716 http://dx.doi.org/10.1038/bjc.2012.450 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Translational Therapeutics
Lin, Y
Richards, F M
Krippendorff, B-F
Bramhall, J L
Harrington, J A
Bapiro, T E
Robertson, A
Zheleva, D
Jodrell, D I
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
title Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
title_full Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
title_fullStr Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
title_full_unstemmed Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
title_short Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
title_sort paclitaxel and cyc3, an aurora kinase a inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493865/
https://www.ncbi.nlm.nih.gov/pubmed/23037716
http://dx.doi.org/10.1038/bjc.2012.450
work_keys_str_mv AT liny paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT richardsfm paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT krippendorffbf paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT bramhalljl paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT harringtonja paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT bapirote paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT robertsona paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT zhelevad paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells
AT jodrelldi paclitaxelandcyc3anaurorakinaseainhibitorsynergiseinpancreaticcancercellsbutnotbonemarrowprecursorcells